See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/42388542
Metabolism of carbosulfan II. Human
interindividual variability in its in vitro hepatic
biotransformation and the identification of...
Article in Chemico-biological interactions · March 2010
DOI: 10.1016/j.cbi.2010.03.024 · Source: PubMed
CITATIONS
READS
21
83
4 authors:
Khaled M. Abass
Petri Reponen
28 PUBLICATIONS 316 CITATIONS
16 PUBLICATIONS 241 CITATIONS
University of Oulu
University of Oulu
SEE PROFILE
SEE PROFILE
Sampo Mattila
Olavi Pelkonen
43 PUBLICATIONS 601 CITATIONS
514 PUBLICATIONS 15,895 CITATIONS
University of Oulu
SEE PROFILE
University of Oulu
SEE PROFILE
All content following this page was uploaded by Khaled M. Abass on 23 December 2016.
The user has requested enhancement of the downloaded file. All in-text references underlined in blue are added to the original document
and are linked to publications on ResearchGate, letting you access and read them immediately.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/copyright
Author's personal copy
Chemico-Biological Interactions 185 (2010) 163–173
Contents lists available at ScienceDirect
Chemico-Biological Interactions
journal homepage: www.elsevier.com/locate/chembioint
Metabolism of carbosulfan II. Human interindividual variability in its in vitro
hepatic biotransformation and the identification of the cytochrome P450
isoforms involved
Khaled Abass a,∗ , Petri Reponen a,b , Sampo Mattila b , Olavi Pelkonen a
a
b
Pharmacology and Toxicology Unit, Institute of Biomedicine, P.O. Box 5000, FI-90014 University of Oulu, Oulu, Finland
Department of Chemistry, P.O. Box 3000, FI-90014 University of Oulu, Oulu, Finland
a r t i c l e
i n f o
Article history:
Received 2 February 2010
Received in revised form 10 March 2010
Accepted 11 March 2010
Available online 20 March 2010
Keywords:
Pesticides
Xenobiotic
Risk assessment
In vitro metabolism
P450
LC–MS
a b s t r a c t
This study aims to characterize interindividual variability and individual CYP enzymes involved in the in
vitro metabolism of the carbamate insecticide carbosulfan. Microsomes from ten human livers (HLM)
were used to characterize the interindividual variability in carbosulfan activation. Altogether eight
phase I metabolites were analyzed by LC–MS. The primary metabolic pathways were detoxification
by the initial oxidation of sulfur to carbosulfan sulfinamide (‘sulfur oxidation pathway’) and activation via cleavage of the nitrogen sulfur bond (N–S) to give carbofuran and dibutylamine (‘carbofuran
pathway’). Differences between maximum and minimum carbosulfan activation values with HLM indicated nearly 5.9-, 7.0, and 6.6-fold variability in the km , Vmax and CLint values, respectively. CYP3A5 and
CYP2B6 had the greatest efficiency to form carbosulfan sulfinamide, while CYP3A4 and CYP3A5 were the
most efficient in the generation of the carbofuran metabolic pathway. Based on average abundances of
CYP enzymes in human liver, CYP3A4 contributed to 98% of carbosulfan activation, while CYP3A4 and
CYP2B6 contributed 57 and 37% to detoxification, respectively. Significant correlations between carbosulfan activation and CYP marker activities were seen with CYP3A4 (omeprazole sulfoxidation), CYP2C19
(omeprazole 5-hydroxylation) and CYP3A4 (midazolam 1′ -hydroxylation), displaying r2 = 0.96, 0.87 and
0.82, respectively. Activation and detoxification pathways were inhibited by ketoconazole, a specific
CYP3A4 inhibitor, by 90–97% and 47–94%, respectively. Carbosulfan inhibited relatively potently CYP3A4
and moderately CYP1A1/2 and CYP2C19 in pooled HLM. These results suggest that the carbosulfan activation pathway is more important than the detoxification pathway, and that carbosulfan activation is
predominantly catalyzed in humans by CYP3A4.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Carbosulfan
[2,3-dihydro-2,2-dimethylbenzofuran-7-yl(dibutylaminothio) methyl carbamate] is a widely used systemic
insecticide with contact and stomach actions. Like other carbamate
insecticides, carbosulfan inhibits cholinesterase and is assigned to
toxicity class II by WHO [1].
There are reports about the metabolism of carbosulfan in the
environment [2,3] and in plants [4]. In mammals three primary
metabolites, 3-hydroxycarbofuran, 3-keto-7-phenolcarbofuran,
and dibutylamine, were detected by TLC in rat in vivo [5].
Moreover, carbofuran and polysulfide derivatives of carbosulfan
were detected in rat stomach by TLC [6]. In male and female
rats in vivo, ten metabolites were identified by TLC and HPLC
∗ Corresponding author. Tel.: +358 8 537 5231; fax: +358 8 537 5247.
E-mail addresses: khaled.m.abass@gmail.com, khaled.megahed@oulu.fi
(K. Abass).
0009-2797/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.cbi.2010.03.024
and major metabolites were confirmed by GC-MS [7]. We have
recently described the in vitro metabolic pathways of carbosulfan in microsomal hepatic preparations from seven mammalian
species including human. The primary metabolic pathways in
these in vitro studies were the detoxification via the initial oxidation of sulfur to carbosulfan sulfinamide (‘sulfur oxidation
pathway’) and the activation via the cleavage of the nitrogen
sulfur bond (N–S) to give carbofuran and dibutylamine (‘carbofuran pathway’). Carbofuran was oxidized to 3-hydroxycarbofuran
and/or 7-phenolcarbofuran, which were further oxidized to 3ketocarbofuran or 3-hydroxy-7-phenolcarbofuran, respectively,
and finally to 3-keto-7-phenolcarbofuran [8].
The cytochrome P450 (CYP) superfamily comprises a broad class
of phase I oxidative enzymes that catalyze many hepatic metabolic
processes [9,10]. Recently, a number of papers have been published
on the activity of human P450s involved in the metabolism of pesticides [11–21].
CYPs variation within the human population is well known
[10] and important for the risk assessment of the chemicals. With
Author's personal copy
164
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
respect to metabolism, variability in CYP activity is among the primary determinants of variability in biotransformation [22]. Studies
investigating the formation of carbosulfan sulfinamide and the carbofuran metabolic pathway by individual cytochrome P450 (CYP)
isoforms have been limited. Therefore, the aims of this study were
(1) to determine the in vitro interindividual variability of enzyme
kinetic parameters in carbosulfan bioactivation in a panel of ten
human hepatic preparations and (2) to characterize the specific
human CYP isoforms involved in carbosulfan biotransformation
by the study of kinetic parameters with the appropriate cDNAexpressed isoforms, correlation studies with model CYP substrate
activities across the human liver bank, and inhibition experiments
with CYP-selective chemical inhibitors and the CYP inhibitions by
carbosulfan itself.
2. Materials and methods
2.1. Chemicals
Carbosulfan,
(2,3-dihydro-2,2-dimethylbenzofuran-7-yl(dibutylaminothio) methylcarbamate), carbofuran (2,3-dihydro2,2-dimethylbenzofurany-7-yl methylcarbamate), 3-hydroxycarbofuran (2,3-dihydro-3-hydroxy-2,2-dimethylbenzofuran-7-yl
methylcarbamate), 3-ketocarbofuran (2,3-dihydro-3-oxy-2,2dimethylbenzofuran-7-yl methylcarbamate), 3-keto-7-phenolcarbofuran
(2,3-dihydro-2,2-dimethyl-3-oxobenzofuran-7-ol),
3-hydroxy-7-phenolcarbofuran (2,3-dihydro-2,2-dimethylbenzofuran-3,7-diol),
and
7-phenolcarbofuran
(2,3-dihydro-2,2
dimethylbenzofuran-7-ol) were purchased from ChemService
(West Chester, PA). Dibutylamine was purchased from SigmaAldrich (Germany) and carbaryl was a kind gift from Agrochem
(Eg). Midazolam was a kind gift from F. Hoffman-La Roche (Basel,
Switzerland), and omeprazole was a gift from Astra Zeneca (Mölndal, Sweden). HPLC-grade solvents were obtained from Rathburn
(Walkerburn, UK) and Labscan (Dublin, Ireland). All other chemicals used were from Sigma-Aldrich (St. Louis, MO) and were of
the highest purity available. Water was freshly prepared in-house
with the Simplicity 185 (Millipore S.A., Molsheim, France) water
purification system and was UP-grade (ultra pure, 18.2 M).
2.2. Human liver microsomes and cDNA-expressed human P450
enzymes
Human liver samples used in this study were obtained from
the University Hospital of Oulu as surplus from organ donors. The
collection of surplus tissue was approved by the Ethics Committee of the Medical Faculty of the University of Oulu, Finland. All
liver samples were of Caucasian race including 4 female and 6 male
between the ages of 21 and 62. Intracerebral hemorrhage was the
primary cause of death. Detailed characteristics of the liver samples are presented in our previous publication [15]. The livers were
transferred to ice immediately after the surgical excision and cut
into pieces, snap-frozen in liquid nitrogen, and stored at −80 ◦ C.
Microsomes were prepared by standard differential ultracentrifugation [23]. The final microsomal pellet was suspended in 100 mM
phosphate buffer, pH 7.4. Protein content was determined by the
Bradford method [24]. Baculovirus insect cell-expressed human
CYPs (CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1,
3A4, 3A5, 3A7 and 4A11) were purchased from BD Biosciences Discovery Labware (Bedford, MA).
2.3. In vitro screening assay of metabolites
The standard incubation mixture contained 150 M carbosulfan, 0.15 mg pooled liver microsomal protein (n = 10), and 1 mM
NADPH in a final volume of 200 l of 0.1 M phosphate buffer (pH
7.4). Carbosulfan was prepared once a week in dimethylsulfoxide
(DMSO; final amount in the reaction medium 1.0%). After a 2-min
incubation at +37 ◦ C in a shaking incubator block (Eppendorf Thermomixer 5436, Hamburg, Germany), the reaction was started by
adding NADPH. The mixture was incubated at +37 ◦ C for 30 min
and the reaction was stopped with 600 l of ice cold acetonitrile
containing an internal standard. All incubations were carried out in
triplicate. After centrifugation at 10,000 × g for 15 min, the supernatant was collected and stored at −20 ◦ C until analyzed.
To measure the main carbosulfan metabolites of recombinantly
expressed CYP enzymes, the standard incubation mixture (200 l)
contained 0.1 M phosphate buffer (pH 7.4), 1 mM NADPH, 100 M
carbosulfan, and recombinantly expressed CYP enzymes (50 pmol
CYP per ml). Incubations were carried out according to the manufacturer’s instructions. Shortly, the reaction was started by adding
recombinant enzymes to the preincubated reaction mixture (2 min
at +37 ◦ C), mixed gently and incubated for 30 min at +37 ◦ C in an
incubator block without agitation. Otherwise, the incubation protocol and analytical method were similar to those for microsomal
incubations.
2.4. Chromatography of the carbosulfan metabolites
Samples were centrifuged before analysis for 10 min at
10,000 × g. Chromatographic separation was carried out with the
Waters Alliance 2690 HPLC system (Waters Corp., Milford, MA). The
column used was a Waters Atlantis T3 (2.1 mm × 100 mm, particle
size of 3 m) together with a Phenomenex C18 2.0 mm × 4.0 mm
precolumn (Phenomenex, Torrance, CA). The temperature of the
column oven was 45 ◦ C. The eluent flow rate was 0.4 ml/min. The
eluents used were ultrapure-grade water containing 0.1% acetic
acid (A) and methanol (B). A linear gradient elution from 5% B to 75%
B in 8 min was applied. Solvent B was thus maintained at 98% for
3 min before re-equilibration (6 min). The total analysis time was
17 min.
2.5. Mass spectrometry
The initial screening of the compounds and accurate mass measurements were carried out using a Micromass LCT (Micromass,
Altrincham, UK) time of flight (TOF) mass spectrometer equipped
with a Z-Spray ionization source. Detailed information was presented in our previous publication [8].
The quantification (multiple reaction monitoring, MRM) and
fragmentation measurements were performed with a Micromass
Quattro II triple quadrupole instrument equipped with a Z-spray
ionization source. The capillary voltage was 4000 V, and desolvation and source temperatures were 280 and 150 ◦ C, respectively.
The collision gas was argon with a CID gas cell pressure of
2.0 × 103 mbar. Nitrogen was used as the drying and nebulizing
gas with flow rates of 450 and 15 l/h. The fragmentation reactions
monitored (MRM), collision energies, and sample cone voltages for
metabolites and the internal standard are presented in Fig. 1. External standards were measured in the beginning, middle, and end of
the experiment to ensure the quality of the analysis. The lower limit
of quantitation was 1 M for all compounds. Intraday coefficients
of variation were less than 20% throughout the quantitation range
of 2.5–300 M.
2.6. Kinetic parameters
To measure the enzyme kinetic parameters in both the microsomal samples and recombinantly expressed CYP enzymes, the
standard incubation mixture contained carbosulfan (final concentrations 2.5–300 M). Incubation mixtures and methods were
the same as mentioned above, except the incubation times were
Author's personal copy
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
165
Fig. 1. Extracted mass chromatograms of carbosulfan metabolites formed by in vitro incubation with mammalian hepatic microsomes. Analytes, exact masses,
fragmentationsa , sample cone voltages (SC), collision energies (CE), and retention times (RT) of analytes used in the measurements by LC–MS are presented.
a
Fragmentations monitored in the quantification are presented in bold.
b
Metabolites were quantified as the protonated dehydrated molecule [M − H2 O + H]+ due to significant in-source fragmentation.
c
Exact mass could be measured only from the protonated dehydrated molecule [M − H2 O + H]+.
20 min for microsomal samples and 30 min for rCYPs. Samples
were analyzed by LC–MS-MS. The kinetic parameters Vmax and
km were calculated using Prism 5.0 (GraphPad Software, Inc., San
Diego, CA) by nonlinear regression. These values were used to
calculate the intrinsic clearance value (Vmax /km ). All results are
expressed as mean ± standard error for three replicates. In the standard experimental conditions used for carbosulfan metabolism, the
reaction rate of carbosulfan metabolites formation was linear at
least up to 0.15 mg of microsomal protein/ml and 30 min incubation
time.
2.8. Inhibition of in vitro metabolism of carbosulfan by
CYP3A4-selective inhibitor
The inhibitory effects of known CYP3A4 isoform-selective
inhibitors on the formation of carbofuran and carbosulfan sulfinamide were evaluated. Formation rates of metabolites were
determined from the reaction mixtures incubated in the presence or absence of ketoconazole 100 M. The incubation conditions
were as described above.
2.9. Inhibition assays
2.7. Correlation with model CYP substrate activities
A bank of ten livers was used to assess the metabolism of carbosulfan in individual livers as well as to correlate the activities
with model CYP substrate activities. A correlation was performed
between the formation of carbosulfan metabolites and each CYP
activity across the human liver bank. Model substrate reactions
used for correlations were the same as those used in the inhibition
studies below. For all data points the mean of duplicate incubations
were used. Bivariate linear Pearson’s correlation coefficients (r2 )
were calculated between metabolite formations and model activities in livers. The software program Prism 5.0 (GraphPad Software,
Inc., San Diego, CA) was used for data analysis.
Ethoxyresorufin-O-deethylation
(EROD)
(CYP1A1/2),
penthoxyresorufin-O-depenthylation
(PROD)
(CYP2B),
7ethoxycoumarin-O-deethylation (ECOD) (multiple CYPs; CYP2A6
predominant) and coumarin-7-hydroxylase (COH) (CYP2A6)
assays were analyzed fluorometrically. EROD and PROD activities
were determined with the method of Burke et al. [25], and ECOD
was analyzed using the method of Greenlee and Poland [26]. COH
activity was analyzed as described previously in detail in Raunio
et al. [27]. The other CYP assays were analyzed by HPLC, and these
included bupropion hydroxylation (CYP2B6) [28], amodiaquine
de-ethylation (CYP2C8) [29], tolbutamide methylhydroxylation
(CYP2C9) [30], dextromethorphan O-demethylation (CYP2D6)
[31], chlorzoxazone 6-hydroxylation (CYP2E1) [32], midazolam
Author's personal copy
166
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
hydroxylation (CYP3A4) [33], and omeprazole 5-hydroxylation
(CYP2C19) and sulfoxidation (CYP3A4) [34]. The instrumentation
and incubation conditions used to assess the enzyme activities
have been described previously in detail by Abass et al. [16].
Inhibition interactions were also determined with the help of
the n-in-one assay described in detail by Turpeinen et al. [35] and
Tolonen et al. [36]. Each inhibition mixture contained 0.5 mg microsomal protein/ml, 0.1 M phosphate buffer (pH 7.4), 1 mM NADPH,
and all ten probe substrates. The amounts of metabolites were
analyzed with LC–MS-MS. The CYP-specific model reactions are
presented in Table 3.
The enzyme activities in the presence of carbosulfan were compared with the control incubations into which only solvent was
added. The IC50 values for inhibitors (concentration causing 50%
reduction of control activity) were determined from duplicate incubations by linear regression analysis from the plot of the logarithm
of inhibitor concentration versus percentage of the activity remaining after inhibition using MicroCal Origin 6.0 (MicroCal Software,
Inc., Northampton, MA).
3. Results
3.1. Identification of carbosulfan metabolites produced in vitro by
human liver microsomes
In our previous in vitro study with microsomes from several mammalian species [8], eight carbosulfan metabolites were
detected from the extracted mass chromatograms and seven of
them were identified with the help of reference standards. In
human liver microsomes, seven of these eight metabolites were
identified, while 7-phenolcarbofuran was detected only in rabbit liver microsomes in our previous study [8]. The unidentified
metabolite could be either a sulfonamide derivative or a hydroxylated carbosulfan. Either of the metabolites or their derivatives
has been detected by TLC in two different studies. 3-hydroxycarbosulfan has been identified as a minor metabolite by TLC in rats
in one study [7] and sulfone derivatives of carbosulfan have been
detected in two separate rat studies [5,7]. In addition, the carbosulfan sulfoxide metabolite has been characterized with an unknown
method in human, mouse, and rat liver microsomes [37]. In the ion
source of a mass spectrometer, hydroxy metabolites of both carbofuran and 7-phenolcarbofuran produced protonated dehydrated
molecules. There is no reason why this should not also happen to
the corresponding carbosulfan hydroxy metabolite. Based on previous reports and missing dehydration of the unidentified metabolite,
we have assumed that it is carbosulfan sulfinamide even though
fragmentation of the analytes also gives some indication of the
hydroxylation of carbosulfan. For the exact identification of this
unidentified metabolite, more experimental work should be performed. Carbosulfan metabolites, their exact masses, fragments
produced in MS-MS, retention times, and analytical parameters are
presented in Fig. 1.
Three of the eight metabolites produced significant insource fragmentation, which could cause errors in the measurements without chromatographic separation. Carbofuran in
particular, which produces some in-source fragmentation to 7phenolcarbofuran, appears in the same chromatograph as an actual
7-phenolcarbofuran metabolite. Because their retention time differs by only 0.2 min, a very large carbofuran peak could occasionally
make the detection of the small 7-phenolcarbofuran peak difficult.
3.2. Kinetic parameters of carbosulfan activation in individual
liver microsomal samples
Interindividual variability in the biotransformation kinetics for
carbosulfan was investigated in hepatic microsomes from ten
Fig. 2. Combined formation rates of carbofuran metabolic pathway illustrated with
HLM22 and HLM31. Details of the experimental conditions were described under
materials and methods. Results are expressed as nmol/(mg protein*min) and represent the mean ± S.D. on three independent determinations.
donors using a wide concentration range (2.5–300 M) of carbosulfan. Metabolites were quantified by triple quadrupole mass
spectrometry and kinetics were calculated for the carbofuran
metabolic pathway, since the active chemical moiety is the most
relevant for chemical risk assessment. Carbosulfan biotransformation followed Michaelis–Menten kinetics as demonstrated by
Eadie-Hofstee plots (V versus V/S).
Detailed data for kinetics parameters are shown in Table 1. Individual 24, HLM24, exhibited the highest affinity, corresponding to
the lowest km (12.8 M), while individual 22 had the lowest, corresponding to the highest km (75.9 M). Individual 22 had the highest
capacity, corresponding to the highest Vmax (27.7 nmol/(mg protein min)), while it was vice versa for individual 31 who had lowest
capacity, corresponding to the lowest Vmax (3.9 nmol/(mg protein min)) (Fig. 2). HLM24 showed the highest CLint rate, whereas
HLM31 displayed the lowest rate (670.8 and 101.1 l/(mg protein min), respectively).
3.3. Interindividual variability in the formation rates of distal
carbofuran metabolites
Since reliable enzyme kinetic parameter estimates could not
be obtained for more distal metabolites of carbofuran when
using carbosulfan as a substrate, metabolite formation rates
were used for interindividual comparisons (Fig. 3). In some
of the individual human hepatic microsomes, the amounts
of 3-keto-7-phenolcarbofuran and 3-hydroxy-7-phenolcarbofuran
formed were below the limits of quantification. Among ten
human liver microsomes examined for carbosulfan metabolism,
HLM31 had the lowest 3-hydroxycarbofuran formation rates,
while HLM22 and HLM28 exhibited the highest formation
rates. The 3-hydroxycarbofuran formation rate varied from
1.0 to 14.9 nmol/(mg protein min) at 300 M carbosulfan, displaying a mean value of 5.9 nmol/(mg protein min) and 15.7fold variation. The rates of 3-ketocarbofuran formation were
0.02–1.1 nmol/(mg protein min), displaying a mean value of
0.3 nmol/(mg protein min) and 73-fold variation. HLM31 displayed the lowest formation rate, while HLM28 had the highest
rate.
Since HLM31 had the lowest 3-hydroxy- and 3-ketocarbofuran
formation rates, their distal metabolites, 3-hydroxy- and 3keto-7-phenolcarbofuran, were not detected at any carbosulfan
concentrations. HLM28 had the highest activity of 3-hydroxy-7-
Author's personal copy
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
167
Table 1
Kinetic parameters of carbofuran metabolic pathway obtained with ten human liver microsomes.a .
Human liver microsomes
Vmax (nmol/(mg protein min))
km (M)
CLint (l/(mg protein min))
HLM20
HLM21
HLM22
HLM23
HLM24
HLM28
HLM29
HLM30
HLM31
HLM32
6.8 ± 0.5
8.7 ± 0.5
27.7 ± 1.6
6.2 ± 0.4
8.6 ± 1.0
26.8 ± 1.4
11.5 ± 0.8
11.6 ± 0.8
3.9 ± 0.2
7.5 ± 0.9
17.3 ± 5.6
33.1 ± 6.9
76.0 ± 11.5
16.4 ± 3.8
12.8 ± 6.6
63.9 ± 9.4
29.3 ± 7.4
24.5 ± 6.4
38.8 ± 4.9
21.1 ± 9.8
391.2
264.4
364.8
380.7
670.8
420.1
394.2
472.9
101.1
353.9
Average
Variation (fold)b
Interindividual variability (fold)c
7.10
5.93
1.76
381.4
6.64
a
Each value represents the mean ± std. error of three determinations. Combined formation rates of all the metabolites of the carbofuran pathway were used for the
calculation of kinetic parameters.
b
Differences between the maximum and minimum observed values.
c
Interindividual variability represents fold differences between mean and the highest value in toxicokinetics as defined by Renwick and Lazarus [58].
phenolcarbofuran and 3-keto-7-phenolcarbofuran formations (2.6
and 0.2 nmol/(mg protein*min)).
3.4. Identification of the P450 isoforms involved in the
metabolism of carbosulfan
To determine which enzymes were responsible for the formation of carbosulfan metabolites, carbosulfan was incubated with
individual human cDNA-expressed P450 isoforms, (CYP1A1, 1A2,
1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, 3A5, 3A7,
and 4A11) and NADPH, and the results are shown in Fig. 4.
Among the isoforms tested, the role of the CYP3A subfamily
appeared to be the most active one to metabolize carbosulfan. Among the CYP2C subfamily members, CYP2C8, CYP2C18,
and CYP2C19 were associated with the carbofuran metabolic
pathway, whereas all tested CYP2C subfamily members were
involved in carbosulfan sulfinamidation. CYP1A1 and CYP2B6
mediated both carbosulfan metabolic pathways. CYP1B1 and
CYP2E1 did not have detectable activity toward carbosulfan
metabolism.
Fig. 3. Interindividual variability in the formation of carbosulfan metabolites. Human liver microsomes, HLM, (0.15 mg protein/ml) were incubated in various carbosulfan
concentrations in a 100 mM phosphate buffer (pH 7.4) for 20 min. Columns represent the mean of three separate determinations and the error bars represent S.D.
Author's personal copy
168
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
Table 2
Kinetic parameters for the formation of carbosulfan metabolites obtained with human recombinant P450s.a .
P450 isoforms
Vmax (nmol/(nmol P450 min))
Carbofuran metabolic pathwayc
CYP1A1
53.5 ± 5.6
CYP1A2
42.8 ± 9.3
CYP2A6
92.2 ± 18.8
CYP2B6
31.0 ± 6.9
CYP2C8
61.7 ± 9.5
CYP2C18
84.7 ± 5.6
CYP2C19
72.9 ± 5.6
CYP3A4
816.1 ± 70.8
CYP3A5
133.5 ± 10.3
CYP3A7
40.2 ± 3.1
Carbosulfan sulfinamide metabolic pathway
CYP1A1
29.2 ± 3.7
CYP2B6
26.9 ± 3.6
CYP2C19
11.6 ± 0.6
CYP3A4
25.3 ± 3.1
CYP3A5
39.9 ± 2.5
CYP3A7
5.6 ± 0.3
km (M)
CLint (l/(nmol P450 min))
Relative contributionb
14.4 ± 7.3
68.2 ± 15.1
178.3 ± 42.4
40.9 ± 15.9
106.4 ± 25.4
174.9 ± 32.7
80.8 ± 21.6
29.9 ± 10.4
7.6 ± 1.5
10.2 ± 3.4
3709.6
626.8
516.9
757.9
580.3
484.4
902.8
27330.9
17528.9
3952.8
n.d.
0.22
0.60
0.27
0.45
n.d.
0.41
98.1
n.d.
n.d.
38.6 ± 18.6
28.0 ± 15.4
93.4 ± 16.0
170.5 ± 57.3
29.7 ± 10.6
30.5 ± 8.0
756.4
961.4
123.7
148.4
1346.3
185.2
n.d.
36.8
6.0
57.2
n.d.
n.d.
n.d., not determined.
a
Vmax and km values represent means ± S.E. of three determinations.
b
Average human hepatic microsomal protein amounts of P450 enzymes are taken from Rostami-Hodjegan et al. [38].
c
Combined formation rates of all the metabolites of the carbofuran pathway were used for the calculation of kinetic parameters.
3.5. Enzyme kinetic analysis
Based on the preliminary screening assays described above
(Figure 4), detailed kinetic analyses were performed for carbosulfan with active cDNA-expressed human P450s. Results of
these analyses are presented in Table 2. Combined formation
rates of all the metabolites of the carbofuran pathway were used
for kinetic calculations. Derivations of the km and Vmax values
for each isoform allowed the calculations of intrinsic clearances.
According to the obtained kinetic values for the carbofuran pathway, the performance of the CYP3A subfamily was the highest.
CYP3A4, CYP3A5, and CYP3A7 showed the highest affinity besides
CYP1A1, corresponding to the lowest km , whereas CYP2A6 and
CYP2C18 had the lowest affinity, corresponding to the highest km .
CYP3A4 and CYP3A5 had the highest capacity, while CYP2B6 had
the lowest. The catalytic efficiency (CLint ) values illustrated that
CYP3A4, CYP3A5, and CYP3A7 were the most efficient CYP isoforms
for carbosulfan biotransformation via the carbofuran metabolic
pathway (27331, 17529 and 3953 l/(nmol P450 min), respectively), whereas CYP2C18 was the least efficient (484.4 l/(nmol
P450 min)).
In the case of the carbosulfan sulfinamide metabolic pathway,
two members of the CYP3A subfamily, CYP3A5 and CYP3A7, had
the highest affinity besides CYP2B6, while CYP3A4 had the lowest. The Vmax value for CYP3A5 was the highest (39.9 nmol/(mg
protein min)), whereas the Vmax of CYP3A7 was the lowest (5.6 nmol/(nmol P450 min)). Vmax /km values illustrated that
CYP3A5, CYP2B6, and CYP1A1 were the most efficient rP450s for
carbosulfan transformation to carbosulfan sulfinamide (1346.3,
961.4, 756.4 l/(nmol P450 min), respectively), whereas CYP2C19
was the least efficient (123.7 l/(nmol P450 min)).
The contributions of the P450 isoforms studied were determined
taking into account the average human hepatic microsomal protein amounts of the main P450s [CYP1A2, 52; CYP2A6, 36; CYP2B6,
11; CYP2C8, 24; CYP2C9, 73; CYP2C19, 14; CYP2D6, 8; CYP2E1, 61;
and CYP3A4, 111 pmol/mg microsomal protein] [38] and the actual
intrinsic clearance values for various P450s. The relative contributions of each P450 enzyme were calculated and are shown in
Table 2. CYP3A4 was the main isoform responsible for the carbofuran and carbosulfan sulfinamide metabolic pathways (98.1 and
57.2%, respectively). In addition, CYP2B6 and CYP2C19 were among
the key enzymes that catalyze carbosulfan sulfinamide formation
(36.8 and 6.0%, respectively).
3.6. Correlation analysis
Fig. 4. Combined formation rates of the carbofuran metabolic pathway and carbosulfan sulfinamide formations by human P450s. Results are expressed as the
metabolite formation rates of duplicate samples.
Quantification of carbosulfan metabolism in vitro by ten individual human liver microsomes was performed with 150 M
carbosulfan and a 20-min incubation time. Combined formation
Author's personal copy
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
169
Fig. 5. Correlation of combined formation rates of the carbofuran metabolic pathway with CYP-mediated activities measured in a panel of 10 HLM with 150 M carbosulfan.
CYP marker activities (range of values and mean ± S.D.), on the X axis, are expressed as pmol/(mg protein*min) and formation rates of the carbofuran metabolic pathway, on
the Y axis, are expressed as nmol/(mg protein*min). Activities are the mean of duplicate determinations. r2 is the correlation coefficient.
Author's personal copy
170
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
rates of all the metabolites of the carbofuran pathway varied from
2.2 to 18.8 nmol/(mg protein min), indicating approximately 8.6fold variation and a mean value of 8.7 nmol/(mg protein min).
The rates of carbosulfan sulfinamide formation in the ten different human liver microsomes were 0.6–1.4 nmol/(mg protein min),
displaying 2.6-fold variation and a mean value of 1.0 nmol/(mg protein min).
Rates derived from individual P450 enzymes exhibited considerable variability among ten liver samples. The specific activities of
P450 isoform-catalyzed reactions in microsomes from ten human
livers and their correlations with combined formation rates of all
the metabolites of the carbofuran metabolic pathway were studied
(Figure 5). High and significant correlations between the carbofuran metabolic pathway and CYP marker activities were seen
with CYP3A4 (omeprazole sulfoxidation), CYP2C19 (omeprazole 5hydroxylation), and CYP3A4 (midazolam 1′ -hydroxylation) with
correlation coefficients (r2 ) of 0.96, 0.87, and 0.82, respectively.
Combined formation rates of the carbofuran metabolic pathway by
human liver microsomes did not correlate significantly with other
specific activities of P450 isoforms (r2 < 0.24). Negative correlation was found with CYP2C9-specific model activities (tolbutamide
hydroxylation).
No correlations were observed between the production of
carbosulfan sulfinamide metabolite by different human liver
microsomes and the specific activities of P450 isoform-catalyzed
reactions in microsomes from ten human livers.
3.7. Inhibition of carbosulfan metabolism by ketoconazole
Different carbosulfan concentrations were incubated with the
CYP3A4 isoform-specific inhibitor, ketoconazole, in pooled human
liver microsomes. As shown in Figure 6, ketoconazole inhibited formation rates of the carbofuran pathway by 90–97% and to a lesser
extent carbosulfan sulfinamide formation (47–94%). The results
suggest that CYP3A4 has a major role in carbosulfan metabolism
at different carbosulfan concentrations.
3.8. Inhibitory interactions of carbosulfan with different human
liver P450s
The effects of carbosulfan on CYP-selective activities were determined in pooled human liver microsomes. The IC50 values for
various CYP-associated activities are collected in Table 3. Carbosulfan inhibited some CYP enzymes with high affinity. The lowest IC50
values for CYP3A4, midazolam 1′ -hydroxylation and omeprazole
sulfoxidation, being 11.2 and 23.8 M, respectively.
Moderate values of 58.3 and 61.9 M were observed for
7-ethoxyresorufin O-deethylation (CYP1A1/2) and omeprazole 5hydroxylation (CYP2C19), respectively. All the other values for
Fig. 6. Effect of CYP3A4 isoform-selective inhibitor, ketoconazole, on the carbofuran
metabolic pathway and carbosulfan sulfinamide formation by HLM. Carbosulfan
was incubated with pooled HLM in the presence of 100 M ketoconazole. Columns
represent the means of two separate determinations and the error bars represent
S.D.
CYP2A6, CYP2B, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP2E1
were higher than 100 M, indicating very low or absent affinity.
Briefly, the same inhibition values were obtained with a cocktail assay for CYP1A2, CYP2C19, and CYP3A4. Moreover, moderate
inhibition with CYP2C9 and CYP2D6 was observed only with the
Table 3
The carbosulfan IC50 values of different CYPs using pooled human liver microsomes with single substrate and n-in-one assays.
CYP
Substrate
Reaction
1A1/2
1A2
2A6
2B
2B6
2C8
2C9
2C19
2D6
2E1
3A4
3A4
3A4
7-ethoxyresorufin
Melatonin
Coumarin
7-pentoxyresorufin
Bupropion
Amodiaquine
Tolbutamide
Omeprazole
Dextromethorphan
Chlorzoxazone
Midazolam
Omeprazole
Omeprazole
O-deethylation
6-hydroxylation
7-hydroxylation
O-dealkylation
Hydroxylation
de-ethylation
Methylhydroxylation
5-hydroxylation
O-demethylation
6-hydroxylation
1’-hydroxylation
Sulfoxidation
3-hydroxylation
IC50 (M)
Single substrate assay
n-in-one assay
58.3
–
>100
>100
>100
>100
>100
61.9
>100
>100
11.2
23.8
–
–
93.0
>100
>100
>100
93.7
16.9
16.3
25.0
>100
20.1
18.3
23.4
Author's personal copy
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
cocktail assay. All the other values were higher than 100 M in
both the single substrate and cocktail assays.
4. Discussion
Carbosulfan is metabolized via two metabolic pathways ([8];
this study): (1) carbosulfan undergoes the initial oxidation of sulfur to carbosulfan sulfinamide (‘sulfur oxidation pathway’) and
(2) the major route is the cleavage of the nitrogen sulfur bond
(N–S) to give carbofuran and dibutylamine (‘carbofuran pathway’).
During the present investigation, seven metabolites produced by
human liver microsomes were identified using LC/MS/MS and six
of them were verified with comparison to reference standards. The
carbofuran metabolic pathway contains products (carbofuran, 3hydroxy-carbofuran, 3-ketocarbofuran), which are more toxic than
the parent carbosulfan [5,39,40]. An acute exposure to carbofuran
inhibits the action of acetylcholinesterase (AChE) in nerve cells and
may cause transient endocrine disruption with increased levels of
progesterone, cortisol, and estradiol and decreased testosterone
levels [41]. Repeated exposure to carbofuran has adverse chronic
effects on a broad spectrum of nervous system functions [42] and
may cause serious reproductive problems. Thus, the toxicity of
carbosulfan is dependent on its biotransformation to carbofuran
and its metabolites. Metabolic intrinsic clearance rates obtained in
pooled human liver microsomes and six mammalian liver microsomes indicated that carbosulfan is activated to the carbofuran
metabolic pathway more efficiently than it is detoxified to carbosulfan sulfinamide [8]. The CLint values (l/(mg protein min))
of the carbofuran metabolic pathway were 55- and 11-fold higher
than those of the carbosulfan sulfinamide metabolic pathway (data
not shown) for individuals HL24 and HL31, representing roughly
the highest and the lowest metabolic rates, respectively. These
differences suggest that the carbofuran metabolic pathway (activation pathway) is the most important metabolic pathway in human
liver.
Human liver microsomes display quite large interindividual
differences in all carbosulfan metabolic pathways. Differences
between the maximum and minimum observed values in ten individual liver microsomes indicated 5.9-, 7.0-, and 6.6-fold variability
in the km , Vmax and CLint values for the carbofuran metabolic pathway, respectively. The up to 7-fold interindividual variability in
the rate of carbosulfan activation, as determined by the difference
between the lowest and highest value, could be the significant
determinant of the toxicity effects. There will be substantial differences in toxic metabolite formation even if different individuals
are exposed to the same quantity of carbosulfan. High metabolizers might be at higher risk for carbosulfan-related toxicity. There
are large interindividual differences in the expression levels and
catalytic activities of CYP enzymes in humans, and these variations
sometimes lead to different susceptibilities of humans to the pharmacological and toxicological actions of drugs, toxic chemicals, and
carcinogens [10,43].
The relatively large interindividual variability in carbosulfan
bioactivation, and partially also in detoxification, seems to be due to
the preponderance of carbosulfan metabolism by CYP3A subfamily
members, especially by CYP3A4 (see below for further discussion).
This became especially apparent in our study on the correlation
between specific P450 isoform-catalyzed reactions in microsomes
from ten human livers and the combined formation rates of all the
metabolites of the carbofuran metabolic pathway. High correlations were observed with CYP3A4 and CYP2C19. The individuals
with the highest levels of CYP3A4 (HLM22 and HLM28) had the
highest Vmax ,of carbofuran pathway and the reverse was true for an
individual (HLM31) who had the lowest levels of CYP3A4 isoform.
These results on correlation analysis together with other experiments on recombinant enzymes collectively suggest that CYP3A
171
subfamily members play a dominant role in the interindividual
variability of carbosulfan activation. Moreover, it is possible that
those individuals with a high CYP3A4 and CYP2C19 content may
be more susceptible to carbosulfan toxicity.
Kinetic characterization showed that carbosulfan metabolism
to carbosulfan sulfinamide and the carbofuran metabolic pathway
were one-phasic; in other words, it can be described as involving one active site or several sites with similar enzyme kinetic
characteristics. Actually, our studies on a large set of recombinant P450 enzymes indicated that several enzymes were able to
metabolize carbosulfan. The carbofuran pathway was the preferable pathway based on values of kinetic parameters obtained with
active recombinant CYPs. Four CYP isoforms, CYP1A1, CYP3A4,
CYP3A5, and CYP3A7 were involved in the carbofuran pathway
with high affinity. Additionally, CYP2C19 and CYP2B6 displayed
some activity towards carbofuran formation. However, it is difficult
to separate the involvement of individual CYPs in the carbofuran
metabolic pathway leading to the formation of more distal carbofuran metabolites, and further studies are required to clarify the
individual contribution of the isoforms involved in minor metabolite formations. Nevertheless, there is strong evidence from earlier
studies that CYP3A4 is the predominant isoform responsible for formation of 3-hydroxycarbofuran, when starting from carbofuran as
the substrate [13].
CYP3A5, CYP2B6, and CYP1A1 were active in carbosulfan sulfinamide formation, whereas CYP3A7, CYP3A4 and CYP2C19 were
less active. All CYPs involved in carbosulfan sulfinamide formation
were participating also in the carbofuran metabolic pathway, but
relative efficiencies differed considerably: CYP2B6 had a preference for the carbosulfan sulfinamide pathway, whereas CYP1A1,
CYP2C19, CYP3A4, CYP3A5, and CYP3A7 were much more active
in the carbofuran pathway (4.9-, 7.3-, 184.2-, 13.0-, and 21.3-fold
more efficient, respectively).
The relative importance of individual isoforms to in vitro and in
vivo clearance is dependent upon the relative abundance of each
isoform. Thus, intrinsic clearance values measured with individual cDNA-expressed enzymes have to be normalized with respect
to the human hepatic microsomal P450 isoenzyme concentrations.
The relative contribution of CYP3A4 to carbosulfan metabolism was
the highest because of both high intrinsic clearance and average
amount. Although CYP1A1 had the highest intrinsic clearance value
for the carbofuran metabolic pathway, its contribution is probably
negligible because the amount of CYP1A1 in the human liver is very
small [9]. Based on the average human hepatic microsomal protein
amounts of the CYP3A subfamily (155 pmol/mg microsomal protein) [38], the CYP3A subfamily contributes to a superior degree to
the carbofuran and carbosulfan sulfinamide metabolic pathways
(99.2 and 96.3%), respectively.
CYP2B6 had a higher affinity (km = 28.0 M) for carbosulfan
sulfinamide formation than CYP3A subfamily members (CYP3A5,
km = 29.7; CYP3A7, 30.5 and CYP3A4, 171 M). However, the calculation of relative contributions of CYPs confirmed the role of the
CYP3A subfamily in the carbosulfan sulfinamide metabolic pathway. CYP2B6 contributes with 0.7% to carbosulfan sulfinamide
formation compared to CYP3A subfamily members.
The observation of the preponderance of CYP3A4 in carbosulfan metabolism, which was based on the average abundances of
CYP enzymes in human liver microsomes, was further confirmed
by the correlation studies (see above) and by the observation that
the in vitro microsomal metabolism of carbosulfan was inhibited by
ketoconazole, a selective inhibitor for CYP3A4/5 [10,43]. Our results
showed that ketoconazole significantly inhibited the carbofuran
metabolic pathway in vitro. Furthermore, carbosulfan inhibited relatively potently the CYP3A4-selective enzyme activity in pooled
human liver microsomes and moderately CYP1A1/2 and CYP2C19.
Inhibitory interactions studies supported the role of CYP3A4 in car-
Author's personal copy
172
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
bosulfan metabolism as CYP3A subfamily members were the P450
isoforms with relatively low km values for carbosulfan metabolism.
Although the CYP3A subfamily, CYP3A4, 3A5, and 3A7, represents about 30% of the total hepatic P450 content and is considered
the most important CYP subfamily in the biotransformation of
xenobiotics [10,44,45], relative abundances of its members are
highly different. CYP3A5 exists in only 10-20% of humans and its
content is equivalent to only about 0.2% of the total P450 amount
[46,47]. The amount of CYP3A7 is very low in adult human livers and
is mainly expressed in embryonic, fetal, and newborn livers, where
it is the predominant CYP form [48,49]. Thus, CYP3A4 is probably
the most important CYP enzyme and it has been shown that it has a
vital role in pesticide metabolism, as demonstrated here for carbosulfan, and furthermore it is involved in the metabolism of almost
all currently tested pesticides. However, chemical structure influences which CYPs mediate the specific reaction, i.e activation or
detoxification. CYP3A4 activate and detoxify parathion, diazinon
and chlorpyrifos while it is mainly involved in carbaryl detoxification to 4-hydroxycarbaryl [50–53]. In our previous study [8], the
catalytic efficiency of the carbofuran metabolic pathway (CLint ) for
minipig, monkey, and human liver microsomes displayed similar
high values, while rat, rabbit, mouse, and dog liver microsomes
had lower values. In view of the current results that CYP3A subfamily members are the main enzymes responsible for carbosulfan
activation, our findings are in agreement with our earlier comparative in vitro study of hepatic drug metabolism of six experimental
animal species and human, in which presumably CYP3A-mediated
midazolam ␣-hydroxylase and omeprazole sulfoxidase activities in
human and monkey liver microsomes were relatively high, while
activities of rat and rabbit liver microsomes were much lower
[54].
Human data are needed for quantitative toxicokinetics comparisons between individuals or between animals and humans
[55,56]. The use of chemical-specific toxicological data instead
of default assessment factors, whenever possible, was proposed
by the International Program on Chemical Safety (IPCS) [57].
Our data concerning the metabolism of carbosulfan in animals
and humans have significant implications for the calculation of
chemical-specific adjustment factors (CSAFs). The uncertainty factor for human variability in toxicokinetics was 1.76-fold, as defined
by Renwick and Lazarus [58] as a variation between the mean and
the highest value. This suggested that interindividual variability, for
the carbosulfan active chemical moiety, in toxicokinetics is within
the standard applied factor for interindividual extrapolation in toxicokinetics. Moreover, we have shown previously that interspecies
differences in toxicokinetics are within the standard applied factor
for species extrapolation in toxicokinetics. However, it should be
kept in mind that these data are restricted to metabolic data from
human and animal liver preparations.
In conclusion, in this study we have identified, by LC/MS/MS,
seven metabolites produced by human liver microsomes and six of
them were verified with comparison to reference standards. The
carbofuran metabolic pathway (activation pathway) is the major
metabolic pathway in human liver microsomes and there is marked
(up to 7-fold) interindividual variability in the carbosulfan activation. We have provided strong evidence that carbosulfan activation
is predominantly catalyzed by CYP3A subfamily members. First, the
recombinant human CYP3A4 was the major enzyme involved in
the metabolism. Second, the formation rate of carbofuran pathway
metabolites correlated significantly with the activity of CYP3A in a
panel of human liver microsomes. Third, the carbofuran metabolic
pathway was potently inhibited by ketoconazole, a strong inhibitor
of CYP3A. Fourth, carbosulfan relatively potently inhibited CYP3A4
activity in pooled human liver microsomes. The data demonstrated
that metabolism of carbosulfan may interfere with other substrates
for the CYP3A family. The inhibitory interactions might be of sig-
nificance at least in those occupational situations where workers
are exposed to the higher pesticide concentrations.
Conflicts of interest
None of the authors has a conflict of interest related to this study.
Acknowledgements
This work was funded by a Ministry of Education-supported
position from the Finnish Graduate School in Toxicology (ToxGS)
and by grants from The Academy of Finland and The Finnish Granting Agency for Technological Research and Innovation (TEKES) and
supported by grants from the Agriculture Foundation of Economic
Association in the Oulu province and Orion-Farmos Research Foundation.
References
[1] C. Tomlin, The Pesticide Manual, 12th ed., BCPC Publications, Berkshire, UK,
2000.
[2] L.P. de Melo Plese, L.C. Paraiba, L.L. Foloni, L.R. Pimentel Trevizan, Kinetics of
carbosulfan hydrolysis to carbofuran and the subsequent degradation of this
last compound in irrigated rice fields, Chemosphere 60 (2005) 149–156.
[3] G.R. Chaudhry, A. Mateen, B. Kaskar, M. Sardessai, M. Bloda, A.R. Bhatti, S.K.
Walia, Induction of carbofuran oxidation to 4-hydroxycarbofuran by Pseudomonas sp. 50432, FEMS Microbiol. Ecol. 214 (2002) 171–176.
[4] C. Soler, J. Mañes, Y. Picó, Determination of carbosulfan and its metabolites in
oranges by liquid chromatography ion-trap triple-stage mass spectrometry, J.
Chromatogr. A 1109 (2006) 228–241.
[5] P.J. Marsden, E. Kuwano, T.R. Fukuto, Metabolism of carbosulfan [2, 3-dihydro2,2-dimethylbenzofuran-7-yl (di-n-butylaminothio)methylcarbamate] in the
rat and house fly, Pestic. Biochem. Physiol. 18 (1982) 38–48.
[6] N. Umetsu, T.R. Fukuto, Alteration of carbosulfan [2,3-dihydro-2,2-dimethyl-7benzofuranyl(di-n-butylaminosulfenyl)methylcarbamate] in the rat stomach,
J. Agric. Food Chem. 30 (1982) 555–557.
[7] FAO/WHO, Pesticide residues in food - 2003: Toxicological evaluations, World
Health Organization, Geneva, 2003.
[8] K. Abass, P. Reponen, S. Mattila, O. Pelkonen, Metabolism of carbosulfan. I.
Species differences in the in vitro biotransformation by mammalian hepatic
microsomes including human, Chem. Biol. Interact. 181 (2009) 210–219.
[9] S. Rendic, F.J. Di Carlo, Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors, Drug Metab. Rev.
29 (1997) 413–580.
[10] O. Pelkonen, M. Turpeinen, J. Hakkola, P. Honkakoski, J. Hukkanen, H. Raunio,
Inhibition and induction of human cytochrome P450 enzymes: current status,
Arch. Toxicol. 82 (2008) 667–715.
[11] J. Tang, J. Tang, K. Amin Usmani, E. Hodgson, R.L. Rose, In vitro metabolism of
fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam, Chem. Biol. Interact. 147 (2004) 319–329.
[12] K.A. Usmani, E.D. Karoly, E. Hodgson, R.L. Rose, In vitro sulfoxidation of
thioether compounds by human cytochrome P450 and flavin-containing
monooxygenase isoforms with particular reference to the CYP2C subfamily,
Drug Metab. Dispos. 32 (2004) 333–339.
[13] K.A. Usmani, E. Hodgson, R.L. Rose, In vitro metabolism of carbofuran by human,
mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol, Chem. Biol. Interact. 150 (2004) 221–332.
[14] F.M. Buratti, A. D’Aniello, M.T. Volpe, A. Meneguz, E. Testai, Malathion bioactivation in the human liver liver: The contribution of different cytochrome P450
isoform, Drug Metab. Dispos. 33 (2005) 295–302.
[15] K. Abass, P. Reponen, J. Jalonen, O. Pelkonen, In vitro metabolism and interaction
of profenofos by human, mouse and rat liver preparations, Pestic. Biochem.
Physiol. 87 (2007) 238–247.
[16] K. Abass, P. Reponen, M. Turpeinen, J. Jalonen, O. Pelkonen, Characterization
of diuron N-demethylation by mammalian hepatic microsomes and cDNAexpressed human cytochrome P450 enzymes, Drug Metab. Dispos. 35 (2007)
1634–1641.
[17] F.M. Buratti, E. Testai, Evidences for CYP3A4 autoactivation in the desulfuration
of dimethoate by the human liver, Toxicology 241 (2007) 33–46.
[18] R.J. Foxenberg, B.P. McGarrigle, J.B. Knaak, P.J. Kostyniak, J.R. Olson, Human
hepatic cytochrome P450-specific metabolism of parathion and chlorpyrifos,
Drug Metab. Dispos. 35 (2007) 189–193.
[19] C.S. Mazur, J.F. Kenneke, Cross-species comparison of conazole fungicide
metabolites using rat and rainbow trout (Onchorhynchus mykiss) hepatic
microsomes and purified human CYP 3A4, Environ. Sci. Technol. 42 (2008)
947–954.
[20] C. Leoni, F.M. Buratti, E. Testai, The participation of human hepatic P450
isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion, Toxicol. Appl. Pharmacol. 233 (2008)
343–352.
Author's personal copy
K. Abass et al. / Chemico-Biological Interactions 185 (2010) 163–173
[21] E.J. Scollon, J.M. Starr, S.J. Godin, M.J. DeVito, M.F. Hughes, In vitro metabolism
of pyrethroid pesticides by rat and human hepatic microsomes and cytochrome
P450 isoforms, Drug Metab. Dispos. 37 (2009) 221–228.
[22] J.C. Lipscomb, T.S. Poet, In vitro measurements of metabolism for application
in pharmacokinetic modeling, Pharmacol. Ther. 118 (2008) 82–103.
[23] O. Pelkonen, E.H. Kaltiala, T.K.I. Larmi, N.T. Karki, Cytochrome P 450 linked
monooxygenase system and drug induced spectral interactions in human liver
microsomes, Chem. Biol. Interact. 9 (1974) 205–216.
[24] M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal.
Biochem. 72 (1976) 248–254.
[25] M.D. Burke, R.A. Prough, R.T. Mayer, Characteristics of a microsomal
cytochrome P-448-mediated reaction. Ethoxyresorufin O-de-ethylation, Drug
Metab. Dispos. 5 (1977) 1–8.
[26] W.F. Greenlee, A. Poland, An improved assay of 7-ethoxycoumarin Odeethylase activity: induction of hepatic enzyme activity in C57BL/6J
and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8tetrachlorodibenzo-p-dioxin, J. Pharmacol. Exp. Ther. 205 (1978) 596–
605.
[27] H. Raunio, J. Valtonen, P. Honkakoski, M.A. Lang, M. Stahlberg, M.A. Kairaluoma,
A. Rautio, M. Pasanen, O. Pelkonen, Immunochemical detection of human liver
cytochrome P450 forms related to phenobarbital-inducible forms in the mouse,
Biochem. Pharmacol. 40 (1990) 2503–2509.
[28] M. Turpeinen, R. Nieminen, T. Juntunen, P. Taavitsainen, H. Raunio, O. Pelkonen, Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in
human liver microsomes in vitro, Drug Metab. Dispos. 32 (2004) 626–
631.
[29] X. Li, A. Bjorkman, T.B. Andersson, M. Ridderstrom, C.M. Masimirembwa,
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe
substrate, J. Pharmacol. Exp. Ther. 300 (2002) 399–407.
[30] T.H. Sullivan-Klose, B.I. Ghanayem, D.A. Bell, Z.Y. Zhang, L.S. Kaminsky, G.M.
Shenfield, J.O. Miners, D.J. Birkett, J.A. Goldstein, The role of the CYP2C9-Leu359
allelic variant in the tolbutamide polymorphism, Pharmacogenetics 6 (1996)
341–349.
[31] T. Kronbach, D. Mathys, J. Gut, T. Catin, U.A. Meyer, High-performance
liquid chromatographic assays for bufuralol 1’-hydroxylase, debrisoquine
4-hydroxylase, and dextromethorphan O-demethylase in microsomes and
purified cytochrome P-450 isozymes of human liver, Anal. Biochem. 162 (1987)
24–32.
[32] R. Peter, R. Bocker, P.H. Beaune, M. Iwasaki, F.P. Guengerich, C.S. Yang, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome
P-450IIE1, Chem. Res. Toxicol. 3 (1990) 566–573.
[33] T. Kronbach, D. Mathys, M. Umeno, F.J. Gonzalez, U.A. Meyer, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4, Mol. Pharmacol.
36 (1989) 89–96.
[34] A. Abelo, T.B. Andersson, M. Antonsson, A.K. Naudot, I. Skanberg, L. Weidolf, Stereoselective metabolism of omeprazole by human cytochrome P450
enzymes, Drug Metab. Dispos. 28 (2000) 966–972.
[35] M. Turpeinen, J. Uusitalo, J. Jalonen, O. Pelkonen, Multiple P450 substrates in a
single run: rapid and comprehensive in vitro interaction assay, Eur. J. Pharm.
Sci. 24 (2005) 123–132.
[36] A. Tolonen, A. Petsalo, M. Turpeinen, J. Uusitalo, O. Pelkonen, In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe
reactions and a single LC/MSMS run: analytical validation and testing with
monoclonal anti-CYP antibodies, J. Mass Spec. 42 (2007) 960–966.
[37] J.H. Kim, C. Chang, J. Moon, H. Lee, J. Lee, H. Park, B. Park, E. Hwang, H. Lee, K.
Liu, Comparative metabolism of insecticide carbosulfan by human, mouse and
rat liver microsomes, Toxicol. Lett. 172 (2007) S211–S1211.
[38] A. Rostami-Hodjegan, A. Rostami-Hodjegan, G.T. Tucker, Simulation and prediction of in vivo drug metabolism in human populations from in vitro data,
Nat. Rev. Drug Discov. 6 (2007) 140–148.
View publication stats
173
[39] M.J. Trevisan, L.R.P. Trevizan, G.C. de Baptista, A.A. Franco, Metabolism of carbosulfan to carbofuran and to 3-hydroxy-carbofuran in orange leaves, Rev. Bras.
Toxicol. 17 (2004) 17–22.
[40] Y. Kinoshita, T.R. Fukuto, Insecticidal properties of N-sulfonyl derivatives of
propoxur and carbofuran, J. Agric. Food Chem. 28 (1980) 1325–1327.
[41] R.T. Goad, J.T. Goad, B.H. Atieh, R.C. Gupta, Carbofuran-induced endocrine disruption in adult male rats, Toxicol. Mech. Methods 14 (2004) 233–239.
[42] C. Wesseling, M. Keifer, A. Ahlbom, R. McConnell, J.D. Moon, L. Rosenstock, C. Hogstedt, Long-term neurobehavioral effects of mild poisonings with
organophosphate and n-methyl carbamate pesticides among banana workers,
Int. J. Occup. Environ. Health 8 (2002) 27–34.
[43] O. Pelkonen, J. Maenpaa, P. Taavitsainen, A. Rautio, H. Raunio, Inhibition and
induction of human cytochrome P450 (CYP) enzymes, Xenobiotica 28 (1998)
1203–1253.
[44] R.J. Riley, A.J. Parker, S. Trigg, C.N. Manners, Development of a generalized,
quantitative physicochemical model of CYP3A4 inhibition for use in early drug
discovery, Pharm. Res. 18 (2001) 652–655.
[45] Y. Liu, H. Hao, C. Liu, G. Wang, H. Xie, Drugs as CYP3A probes, inducers, and
inhibitors, Drug Metab.Rev. 39 (2007) 699.
[46] T. Aoyama, S. Yamano, D.J. Waxman, D.P. Lapenson, U.A. Meyer, V. Fischer,
R. Tyndale, T. Inaba, W. Kalow, H.V. Gelboin, F.J. Gonzalez, Cytochrome P450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially
expressed in adult human liver. cDNA and deduced amino acid sequence and
distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism
of steroid hormones and cyclosporine, J. Biol. Chem. 264 (1989) 10388–10395.
[47] A.D. Rodrigues, Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native
human liver microsomes, Biochem. Pharmacol. 57 (1999) 465–480.
[48] R. Kitamura, K. Sato, M. Sawada, S. Itoh, M. Kitada, M. Komori, T. Kamataki,
Stable expression of cytochrome P450IIIA7 cDNA in human breast cancer cell
line MCF-7 and its application to cytotoxicity testing, Arch. Biochem. Biophys.
292 (1992) 136–140.
[49] J. Hakkola, H. Raunio, R. Purkunen, S. Saarikoski, K. Vähäkangas, O. Pelkonen,
R.J. Edwards, A.R. Boobis, M. Pasanen, Cytochrome P450 3A expression in the
human fetal liver: evidence that CYP3A5 is expressed in only a limited number
of fetal livers, Biol. Neonate 80 (2001) 193–201.
[50] J. Tang, Y. Cao, R.L. Rose, A.A. Brimfield, D. Dai, J.A. Goldstein, E. Hodgson,
Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human,
mouse, and rat liver microsomes, Drug Metab. Dispos. 29 (2001) 1201–1204.
[51] J. Tang, Y. Cao, R.L. Rose, E. Hodgson, In vitro metabolism of carbaryl by human
cytochrome P450 and its inhibition by chlorpyrifos, Chem. Biol. Interact. 141
(2002) 229–241.
[52] E. Mutch, A.K. Daly, J.B. Leathart, P.G. Blain, F.M. Williams, Do multiple
cytochrome P450 isoforms contribute to parathion metabolism in man? Arch.
Toxicol. 77 (2003) 313–320.
[53] E. Mutch, F.M. Williams, Diazinon, chlorpyrifos and parathion are metabolised
by multiple cytochromes P450 in human liver, Toxicology 224 (2006) 22–32.
[54] M. Turpeinen, C. Ghiciuc, M. Opritoui, L. Tursas, O. Pelkonen, M. Pasanen, Predictive value of animal models for human cytochrome P450 (CYP)-mediated
metabolism: A comparative study in vitro, Xenobiotica 37 (2007) 1367–1377.
[55] A. Falk-Filipsson, A. Hanberg, K. Victorin, M. Warholm, M. Wallén, Assessment
factors—applications in health risk assessment of chemicals, Environ. Res. 104
(2007) 108–127.
[56] B. Meek, A. Renwick, C. Sonich-Mullin, Practical application of kinetic data in
risk assessment—an IPCS initiative, Toxicol. Lett. 138 (2003) 151–160.
[57] WHO/IPCS, Chemical-specific adjustment factors for interspecies differences and human variability: guidance document for use of data in
dose/concentration-response assessment. International Program on Chemical
Safety, WHO/UNEP/ILO, World Health Organization, Geneva, 2005.
[58] A.G. Renwick, N.R. Lazarus, Human variability and noncancer risk assessment—
an analysis of the default uncertainty factor, Regul. Toxicol. Pharm. 27 (1998)
3–20.